ストックスクリーナーアプリを入手
3.91
2.36%
0.09
アフターアワーズ：
3.91
前日終値:
$3.82
開ける：
$3.82
24時間の取引高:
185.66K
Relative Volume:
0.60
時価総額：
$211.16M
収益：
$77.36M
当期純損益:
$-38.43M
株価収益率:
-5.2781
EPS:
-0.7408
ネットキャッシュフロー:
$-29.92M
1週間 パフォーマンス:
+12.36%
1か月 パフォーマンス:
+6.54%
6か月 パフォーマンス:
+8.61%
1年 パフォーマンス:
+55.16%
1日の値動き範囲:
$3.82
$3.96
1週間の範囲:
$3.378
$3.96
52週間の値動き範囲:
$2.3998
$9.2362
Sight Sciences Inc Stock (SGHT) Company Profile
Compare SGHT vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SGHT
Sight Sciences Inc
|
3.91 | 206.30M | 77.36M | -38.43M | -29.92M | -0.7408 |
ABT
Abbott Laboratories
|
101.56 | 175.59B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
341.24 | 132.47B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.10 | 113.14B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
64.61 | 94.85B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
78.20 | 45.09B | 6.07B | 1.06B | 1.34B | 1.8063 |
Sight Sciences Inc Stock (SGHT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-05 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-08-08 | アップグレード | Lake Street | Hold → Buy |
| 2024-12-06 | 開始されました | UBS | Buy |
| 2024-11-04 | ダウングレード | Lake Street | Buy → Hold |
| 2024-08-21 | 開始されました | Lake Street | Buy |
| 2023-09-12 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-09-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-09-12 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-08-24 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-07-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-01-06 | アップグレード | Stifel | Hold → Buy |
| 2022-10-04 | 開始されました | Needham | Hold |
| 2022-07-26 | 開始されました | Stifel | Hold |
| 2022-02-03 | 開始されました | William Blair | Outperform |
| 2022-01-07 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
すべてを表示
Sight Sciences Inc (SGHT) 最新ニュース
Sight Sciences wins $34M patent ruling against Alcon - MSN
KCK LTD. Significantly Reduces Stake in Sight Sciences Inc - GuruFocus
SGHT: Momentum builds for interventional glaucoma and dry eye, with innovation and adoption accelerating - TradingView — Track All Markets
If You Invested $1,000 in Sight Sciences, Inc. (SGHT) - Stock Titan
Form 4Statement of changes in beneficial ownership of securities - ADVFN
Sight Sciences CLO Hayden sells shares worth $48,851 By Investing.com - Investing.com India
Sight Sciences CLO Hayden sells shares worth $48,851 - Investing.com
Sight Sciences CFO Rodberg sells $25,670 in shares - Investing.com
Sight Sciences CFO Rodberg sells $25,670 in shares By Investing.com - Investing.com Canada
Sight Sciences (NASDAQ: SGHT) CFO sells 7,231 shares to cover RSU taxes - Stock Titan
Sight Sciences (SGHT) legal chief sells 13,761 shares for RSU tax obligations - Stock Titan
KCK Ltd. reports 1.44M shares in Sight Sciences (SGHT) — 2.7% stake - Stock Titan
Bull Bear: Does ITRI offer margin of safetyWeekly Profit Analysis & Smart Investment Allocation Tips - baoquankhu1.vn
Citi Maintains Sight Sciences(SGHT.US) With Hold Rating, Cuts Target Price to $4.35 - Moomoo
Affiliate notice: SGHT (NASDAQ: SGHT) proposes common-share sale tied to vesting - Stock Titan
SGHT (NASDAQ: SGHT) sale notice: 13,761 restricted shares vesting - Stock Titan
Published on: 2026-04-05 14:40:16 - baoquankhu1.vn
SGHT SEC FilingsSight Sciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Taylor, EVP, operations & R&D, sells $10.6k in Sight Sciences (SGHT) - Investing.com Australia
Insider Selling: Sight Sciences (NASDAQ:SGHT) CTO Sells 8,168 Shares of Stock - MarketBeat
Taylor, EVP, operations & R&D, sells $10.6k in Sight Sciences (SGHT) By Investing.com - Investing.com South Africa
Sight Sciences (NASDAQ:SGHT) EVP Brenton Taylor Sells 2,869 Shares - MarketBeat
Sight Sciences (NASDAQ:SGHT) CEO Sells 29,244 Shares - MarketBeat
Sight Sciences CEO Badawi sells $108k in shares By Investing.com - Investing.com India
[Form 4] Sight Sciences, Inc. Insider Trading Activity - Stock Titan
Sight Sciences CEO Badawi sells $108k in shares - Investing.com
Sight Sciences (SGHT) CTO tax-related sale of 8,168 shares disclosed - Stock Titan
Sight Sciences (SGHT) EVP Brenton sells 2,869 shares for RSU tax obligations - Stock Titan
Sight Sciences executive plans $90K stock sale - National Today
Alison Bauerlein plans sale of 25,874 shares (SGHT) - Stock Titan
Insider sale notice: SGHT (NASDAQ: SGHT) 8,168 restricted shares - Stock Titan
SGHT PE Ratio & Valuation, Is SGHT Overvalued - Intellectia AI
Sight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting - The Manila Times
Sight Sciences' Interventional Technologies for Glaucoma and Dry Eye Disease to Be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting - 富途牛牛
SGHT (NASDAQ: SGHT) files Form 144 to sell 29,244 vested shares - Stock Titan
Proposed share sales at SGHT (NASDAQ: SGHT) include 2,293 and 576 shares - Stock Titan
Aug Rallies: Is Sight Sciences Inc a top pick in the sectorTrade Risk Summary & Target Return Focused Stock Picks - baoquankhu1.vn
Sight Sciences wins $34M in Alcon patent case, ongoing royalty By Investing.com - Investing.com South Africa
Sight Sciences Wins $34 Million Patent Infringement Case Against Alcon, Secures Ongoing Royalties Through 2028 - Minichart
Sight Sciences wins $34M in Alcon patent case, ongoing royalty - Investing.com Australia
Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th - GlobeNewswire
Del. Judge Upholds $34M Verdict In Glaucoma Patent Feud - Law360
Lake Street Maintains Sight Sciences(SGHT.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Published on: 2026-03-31 02:42:17 - baoquankhu1.vn
Sight Sciences U.S. district court issued order on post-trial motions in patent infringement case against Alcon originally filed on Sep 16, 2021 - marketscreener.com
Sight Sciences Inc (SGHT) 財務データ
収益
当期純利益
現金流量
EPS
2.40%
0.00%
大文字化:
|
ボリューム (24 時間):